Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
WVE Price/Volume Stats
Current price | $6.03 | 52-week high | $7.67 |
Prev. close | $6.04 | 52-week low | $3.15 |
Day low | $5.89 | Volume | 170,768 |
Day high | $6.16 | Avg. volume | 929,665 |
50-day MA | $4.99 | Dividend yield | N/A |
200-day MA | $4.90 | Market Cap | 737.37M |
WVE Stock Price Chart Interactive Chart >
WVE POWR Grades
- Growth is the dimension where WVE ranks best; there it ranks ahead of 92.9% of US stocks.
- WVE's strongest trending metric is Value; it's been moving up over the last 26 weeks.
- WVE's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).
WVE Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for WVE is -2.11 -- better than just 4.47% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -4.9 for WAVE LIFE SCIENCES LTD; that's greater than it is for only 3.67% of US stocks.
- Revenue growth over the past 12 months for WAVE LIFE SCIENCES LTD comes in at 1,947.62%, a number that bests 99.68% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to WAVE LIFE SCIENCES LTD are VXRT, ZYME, VCNX, FDMT, and PRTA.
- WVE's SEC filings can be seen here. And to visit WAVE LIFE SCIENCES LTD's official web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- WVE's EV/EBIT ratio is -4.6; this is 131.51% lower than that of the median Healthcare stock.
- WVE's price/sales ratio has moved down 2262.5 over the prior 99 months.
Below are key valuation metrics over time for WVE.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
WVE | 2023-12-29 | 5.9 | -12.4 | -5.9 | -4.6 |
WVE | 2023-12-28 | 5.9 | -12.4 | -5.9 | -4.6 |
WVE | 2023-12-27 | 5.9 | -12.5 | -5.9 | -4.7 |
WVE | 2023-12-26 | 5.8 | -12.3 | -5.8 | -4.6 |
WVE | 2023-12-22 | 5.7 | -11.9 | -5.7 | -4.4 |
WVE | 2023-12-21 | 5.8 | -12.3 | -5.8 | -4.6 |
WVE Growth Metrics
- The year over year cash and equivalents growth rate now stands at -58.45%.
- Its 3 year revenue growth rate is now at 166.66%.
- Its 5 year net income to common stockholders growth rate is now at -187.28%.
The table below shows WVE's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 4.175 | -101.374 | -152.899 |
2022-06-30 | 40.313 | -103.912 | -120.125 |
2022-03-31 | 42.714 | -84.491 | -117.595 |
2021-12-31 | 40.964 | -88.993 | -122.245 |
2021-09-30 | 48.638 | -113.375 | -116.249 |
2021-06-30 | 15.665 | -105.363 | -143.119 |
WVE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- WVE has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 311th of 680 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.060 | 1 | -4.284 |
2021-03-31 | 0.061 | 1 | -4.798 |
2020-12-31 | 0.078 | 1 | -7.715 |
2020-09-30 | 0.050 | 1 | -5.619 |
2020-06-30 | 0.047 | 1 | -5.196 |
2020-03-31 | 0.055 | 1 | -4.843 |
WVE Price Target
For more insight on analysts targets of WVE, see our WVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $9.86 | Average Broker Recommendation | 1.64 (Moderate Buy) |
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular DystrophyFORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatme |
Wave Life Sciences Ltd.'s (NASDAQ:WVE) recent 35% pullback adds to one-year year losses, institutional owners may take drastic measuresKey Insights Institutions' substantial holdings in Wave Life Sciences implies that they have significant influence over... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Wave Life Sciences Prices $100 Million Public Offering of Ordinary SharesCAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, b |
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsCAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave |
WVE Price Returns
1-mo | 18.24% |
3-mo | 19.41% |
6-mo | 4.87% |
1-year | 38.62% |
3-year | -14.95% |
5-year | -84.48% |
YTD | 19.41% |
2023 | -27.86% |
2022 | 122.93% |
2021 | -60.10% |
2020 | -1.81% |
2019 | -80.93% |
Continue Researching WVE
Want to see what other sources are saying about Wave Life Sciences Ltd's financials and stock price? Try the links below:Wave Life Sciences Ltd (WVE) Stock Price | Nasdaq
Wave Life Sciences Ltd (WVE) Stock Quote, History and News - Yahoo Finance
Wave Life Sciences Ltd (WVE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...